A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

Trial Details

  • 350 patients will be taking part in this study
  • Condition: Ulcerative Colitis
  • Intervention: Drug: Etrolizumab Drug: Placebo
  • Clinic: GI Research Institute Suite 770-1190 Hornby Street, Vancouver BC


This Phase III, double blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in patients with moderately to severely active ulcerative colitis (UC) who are naïve to tumor necrosis factor (TNF) inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Full Trial Details


Dr. Brian Bressler

Brian bressler headshot for dt trial listings